Aldevron News / Aldevron

Plasmid DNA Insights: Expanded Focus on CMC in Gene & Cell Therapy Development

Gene and cell therapy developers are contending with the implications of the evolving regulatory environment while trying to progress programs as quickly as possible to address unmet needs and secure first-mover advantage in competitive indications. Regulators are facilitating efforts to truncate development timelines through a series of designations that can expedite programs while also making efforts to implement standardization.

Read More

In the News: Aldevron Expands Manufacturing Capabilities in Madison

On February 10, Aldevron hosted a virtual celebration of its lab facility expansion in Madison.
 
Aldevron produces the raw materials that allow clients to make groundbreaking therapies, and its protein business unit has operated within University Research Park since 2009. The facility’s growth from 8,000 to nearly 30,000 square feet includes a new 3,500-square-foot fermentation suite and will allow the company to expand its projects’ scope and scale.
 
Read the full article from University of Wisconsin-Madison   here.
 
Additionally, Tom Foti, President of Aldevron's Protein Business Unit provided a virtual tour, which you can view below!
Read More

Advancing Direct Enzyme Delivery for Therapeutic Genome Editing In Vivo

Genome editing enzymes such as Cas9 have been successfully employed to target different genetic disorders in model systems, and ex vivo approaches have demonstrated the clinical potential of this technology. However, the challenge of delivering such corrective enzymes in vivo represents a substantial barrier to therapeutic translation.  

Viral vectors—refined during their use in traditional gene therapy—represent the most widely-used delivery platform in preclinical work, and nanoparticles are quickly maturing into a comparably powerful vehicle. Direct delivery of pre-formed CRISPR enzymes has recently emerged as an appealing strategy for enabling therapeutic editing in vivo.  

Read More

In the News: Aldevron to Host Virtual Ribbon Cutting for Madison Site

Aldevron recently announced its upcoming virtual ribbon cutting event, which will take place on Wednesday, February 10 at 12:00 PM CST. Its focus will be the company's investments in key areas, expanding Aldevron's ability to enable clients' breakthroughs in the emerging field of genetic medicine, further impacting patients and achieving the company's mission.

Read More

In the News: Aldevron Now Offering AAV Rep/Cap Plasmids For Viral Vector Production

Aldevron announced today the immediate availability of rep/cap plasmids pALD-AAV2, AAV5 and AAV6 to support AAV viral vector manufacturing. All three rep/cap plasmids are immediately available at Research Grade. Additionally, pALD-AAV6 is immediately available at the GMP-Source® quality level, while pALD-AAV2 and pALD-AAV5 will be made available based on market demand. The plasmids are royalty free for all applications in support of pre-clinical activities through clinical development and commercial production.

Read More

Aldevron Honored at 2021 State of the State Address for its 40+ COVID-19 Programs

The Joint Session of the State of North Dakota’s 67th Legislative Assembly held its opening sessions earlier this week, and featured Governor Doug Burgum’s 2021 State of the State address. Burgum reflected on the progress and challenges of the past year, calling for bold action and investments in infrastructure and other priorities to position the state for a bright future.

Read More

Aldevron Names Matt Johnson Vice President of Information Technologies

Aldevron, a global leader in the manufacture of plasmid DNA, mRNA and proteins, announced the appointment of Matt Johnson as Vice President of Information Technologies (IT). In this newly-created executive role, Johnson will lead the IT team to ensure successful implementation and operation of key technology strategies.

Read More